Document is current
Any future updates will be listed below
-
Authors
Seiki, Yusuke
Ikezawa, Kenji https://orcid.org/0000-0001-7517-8960
Watsuji, Ko
Urabe, Makiko
Kai, Yugo
Takada, Ryoji
Yamai, Takuo
Mukai, Kaori
Nakabori, Tasuku
Uehara, Hiroyuki
Ishibashi, Miki
Ohkawa, Kazuyoshi
- License Information
-
More Information
Article History
Received: 2 November 2023
Accepted: 30 April 2024
First Online: 10 May 2024
Declarations
:
: Ikezawa reports honoraria for lectures from Taiho Pharmaceutical, Yakult Honsha, Ono Pharmaceutical, MSD, Myriad Genetics, ASAHI KASEI PHARMA, Nihon Servier, and Incyte Biosciences Japan, and research funding from ASKA Pharmaceutical. Takada reports honoraria for lectures from Hisamitsu Pharmaceutical, Novartis, and TEIJIN PHARMA. Yamai reports honoraria for lectures from Taiho Pharmaceutical and Yakult Honsha. Ohkawa reports honoraria for lectures from Eisai, Chugai Pharmaceutical, Yakult Honsha, Incyte Biosciences Japan, Takeda, Gilead and Hisamitsu, and research grants from Towa Pharmaceutical and Sumitomo Chemical. The other authors have no conflict of interest.
: This study was approved by the Institutional Review Board of Osaka International Cancer Institute (Approval No.:18225-8) and was designed and executed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments.
